Aimin Jiang - Search Results

Year	Number of Results
2000	1
2004	1
2005	2
2007	1
2008	2
2009	1
2010	1
2012	1
2013	3
2014	2
2015	4
2016	4
2017	4
2018	7
2019	12
2020	28
2021	22
2022	33
2023	22
2024	18

1

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.

Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, Liu Z, Cheng Q, Zhang J, Luo P. Zhou C, et al. Among authors: jiang a. EClinicalMedicine. 2023 Apr 21;59:101967. doi: 10.1016/j.eclinm.2023.101967. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37131541 Free PMC article.

2

Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment.

Gao Z, Bai Y, Lin A, Jiang A, Zhou C, Cheng Q, Liu Z, Chen X, Zhang J, Luo P. Gao Z, et al. Among authors: jiang a. Mol Cancer. 2023 Feb 15;22(1):31. doi: 10.1186/s12943-023-01722-0. Mol Cancer. 2023. PMID: 36793048 Free PMC article. Review.

3

Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma.

Jiang A, Wang J, Liu N, Zheng X, Li Y, Ma Y, Zheng H, Chen X, Fan C, Zhang R, Fu X, Yao Y. Jiang A, et al. Front Genet. 2022 Jan 27;13:833797. doi: 10.3389/fgene.2022.833797. eCollection 2022. Front Genet. 2022. PMID: 35154287 Free PMC article.

4

Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.

Fu C, Jiang A. Fu C, et al. Among authors: jiang a. Front Immunol. 2018 Dec 20;9:3059. doi: 10.3389/fimmu.2018.03059. eCollection 2018. Front Immunol. 2018. PMID: 30619378 Free PMC article. Review.

5

Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis.

Gu T, Jiang A, Zhou C, Lin A, Cheng Q, Liu Z, Zhang J, Luo P. Gu T, et al. Among authors: jiang a. Int J Cancer. 2023 Feb 1;152(3):480-495. doi: 10.1002/ijc.34332. Epub 2022 Nov 3. Int J Cancer. 2023. PMID: 36274626 Free article.

6

Plasmacytoid Dendritic Cells and Cancer Immunotherapy.

Fu C, Zhou L, Mi QS, Jiang A. Fu C, et al. Among authors: jiang a. Cells. 2022 Jan 11;11(2):222. doi: 10.3390/cells11020222. Cells. 2022. PMID: 35053338 Free PMC article. Review.

7

Editorial: Adaptive immune resistance in cancer therapy.

Jiang A, Chen O, Liu Z, Cai H, Wang L, Qi L. Jiang A, et al. Front Pharmacol. 2023 Aug 25;14:1277902. doi: 10.3389/fphar.2023.1277902. eCollection 2023. Front Pharmacol. 2023. PMID: 37693895 Free PMC article. No abstract available.

8

The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?

Jiang A, Liu N, Wang J, Zheng X, Ren M, Zhang W, Yao Y. Jiang A, et al. Front Immunol. 2022 Dec 5;13:1022228. doi: 10.3389/fimmu.2022.1022228. eCollection 2022. Front Immunol. 2022. PMID: 36544757 Free PMC article. Review.

9

DC-Based Vaccines for Cancer Immunotherapy.

Fu C, Zhou L, Mi QS, Jiang A. Fu C, et al. Among authors: jiang a. Vaccines (Basel). 2020 Nov 26;8(4):706. doi: 10.3390/vaccines8040706. Vaccines (Basel). 2020. PMID: 33255895 Free PMC article. Review.

10

DC-Derived Exosomes for Cancer Immunotherapy.

Yao Y, Fu C, Zhou L, Mi QS, Jiang A. Yao Y, et al. Among authors: jiang a. Cancers (Basel). 2021 Jul 21;13(15):3667. doi: 10.3390/cancers13153667. Cancers (Basel). 2021. PMID: 34359569 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

154 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year